Jones Tulloch

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.

Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.